Key result
SIN-1 (0.4 mg IC or IV) had no influence on ischemic parameters in ECG, hemodynamics, or angina severity compared to placebo, showing no direct myocardial anti-ischemic response.
Why the study?
Does SIN-1 improve ischemic parameters in patients when administered via intracoronary or intravenous routes?
Population
21 patients (3 groups of 7 patients each) evaluated for myocardial ischemia
Comparison
0.4 mg SIN-1 administered via either the… vs Placebo
Design
RCT, randomized, double-blind
Authors
Loading...
No direct myocardial anti-ischemic effect from low-dose SIN-1; confirms peripheral vascular mediation and directs trials to vascular endpoints.
RCT (n=21)
Double-blind
randomized
Does SIN-1 improve ischemic parameters in patients when administered via intracoronary or intravenous routes?
Low-dose SIN-1 administered intravenously or intracoronarily does not exert direct myocardial anti-ischemic effects, indicating its clinical efficacy relies on peripheral and vascular mechanisms.
Kober et al. (1993) conducted an RCT in Ischemia / Angina (n=21). SIN-1 vs. Placebo was evaluated on Ischemic parameters in surface and intracoronary ECG. SIN-1 (0.4 mg IC or IV) had no influence on ischemic parameters in ECG, hemodynamics, or angina severity compared to placebo, showing no direct myocardial anti-ischemic response.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: